Tattoos causing local and even generalized lymphadenopathies including sarcoidosis.

Among included reports, localized tattoo-associated lymphadenopathy was less common than generalized/systemic involvement. In total, 15 of 33 case reports described 16 patients with localized manifestation, predominantly affecting axillary [ 3 , 14 , 15 , 18–21 ], cervical [ 20 , 22 ], and inguinal lymph nodes [ 4 , 17 , 23 ] draining tattooed upper limbs, trunk, and lower limbs [ 18 , 20 , 23 ]. In most patients, the lymphadenopathy was unilateral and corresponding anatomically to the drainage area of the tattooed skin [ 14 , 24 ]. By contrast, the remaining three cases showed atypical bilateral involvement within single drainage regions [ 9 , 16 , 17 ], including extensive pelvic and para-aortic pigment deposition from a left thigh tattoo described by Tamura and colleagues [ 17 ]. The time elapsed since the tattooing procedure was reported in 11 cases and ranged from 5 months to 30 years (median: 3 years) [ 9 , 14 , 23 ]. In addition, two cases developed localized lymphadenopathy within days following laser tattoo removal [ 22 ]. Tattooed patients presenting with localized lymphadenopathies were typically young adults, with a median age of 31.5 years (range: 21–71 years) and a balanced sex distribution [ 20 , 22 , 25 ]. Most cases were discovered incidentally during staging or follow-up for malignancy or other clinical conditions [ 3 , 4 , 17 ], whereas 10 out of 16 patients presented with a palpable mass [ 9 , 21 , 24 ]. The specific lymph node size was reported in 10 patients, with the largest diameter ranging from 1 to 3.9 cm (median: 1.9 cm) [ 15 , 20 , 23 ]. Nodes were generally mobile and painless, although six patients reported painful swelling or tenderness of the affected lymph node [ 9 , 18 , 21 ]. Incidental detection most commonly occurred during oncologic staging or follow-up for malignancies, including breast, vulvar, thyroid cancer, and melanoma [ 14 , 16 , 19 , 25 ], as well as during laparoscopy for suspected endometriosis [ 4 ]. In contrast, one patient presented with pronounced axillary pain and swelling, resulting in markedly reduced shoulder range of motion due to compression-induced brachial plexus involvement by an enlarged lymph node [ 18 ]. Diagnostic evaluation typically included physical examination, laboratory testing such as complete blood count, comprehensive metabolic panel, inflammatory markers, tumor markers, and serologic testing for infectious diseases [ 4 ,  20 ], as well as ultrasound and cross-sectional imaging with CT or MRI [ 15 , 18 ]. In several cases, PET-CT revealed hypermetabolic lymph nodes that were initially interpreted as suspicious for malignancy [ 15 , 16 , 20 ], prompting fine-needle aspiration cytology or excisional biopsy, when cytology was non-diagnostic [ 3 , 20 ]. Histopathological examination was performed in all 14 non-laser localized cases. Histology consistently demonstrated pigment-laden macrophages, predominantly within dilated sinuses, associated with reactive lymphoid hyperplasia and no evidence of malignancy [ 9 , 15 ]. Importantly, none of the reports described loss of normal lymph node architecture, which was explicitly noted as preserved in five cases [ 17 , 25 ]. Consequently, most patients underwent surgical removal of at least one affected lymph node, either during cancer surgery or as an excisional biopsy for diagnostic clarification [ 14 , 16 , 17 ]. In several cases, lymphadenectomy or sentinel lymph node biopsy performed for suspected melanoma or other malignancies incidentally revealed tattoo pigment-induced lymphadenopathy [ 16 , 25 ]. In contrast, a minority of patients was evaluated by fine-needle aspiration or core needle biopsy alone, with no further intervention once pigment-related lymphadenopathy was confirmed [ 3 , 9 ]. Systematic clinical follow-ups were rarely reported [ 9 , 24 ]. Acute localized lymphadenopathy occurring days after laser tattoo removal resolved spontaneously within weeks without any intervention in both reported cases [ 22 ]. Symptom resolution was also described in other cases [ 22 , 23 ], including complete recovery following brachial plexus decompression in one case of compressive neuropathy [ 18 ], as well as improvement of pain after lymph node excision in others [ 21 , 23 ]. However, in one patient with silicone breast implants, tattoo pigment-induced lymphadenopathy recurred after 2 years. Repeat excision revealed both tattoo pigment and silicone cystic spaces, which had not been present initially [ 21 ]. Notably, no case described progression of a tattoo pigment-affected lymph node to malignant disease during the reported follow-up period [ 4 , 15 ]. Generalized tattoo-associated lymphadenopathies were reported in 18 of 33 reports, with confirmed sarcoidosis in 13 patients. Among these, 12 cases demonstrated non-caseating granulomas upon histopathological examination [ 5 , 10 , 26 ], while one fulfilled clinical criteria for Löfgren syndrome without histologic confirmation [ 8 ]. Hilar lymph nodes were most frequently involved in 14 cases, followed by mediastinal lymphadenopathy in nine cases, predominantly but not exclusively in sarcoidosis [ 27–30 ]. Additional nodal stations, including axillary, cervical, and inguinal regions, were affected in eight cases [ 31–33 ]. Unlike localized presentations, affected lymph nodes rarely corresponded anatomically to tattoo drainage sites [ 34–36 ]. A notable exception was a case with a permanent eyebrow makeup associated with cervical, submandibular, and hilar lymphadenopathy [ 37 ]. The time interval between tattooing and clinical presentation of generalized lymphadenopathy was reported in 10 cases and ranged from 2 months to 25 years (median: 2.5 years) [ 2 , 7 , 30 ]. In two reports, sarcoidosis onset followed special immune-modulating triggers, occurring a week after SARS-CoV-2 vaccination in one case [ 37 ] and 60 days following initiation of immune checkpoint inhibitor therapy for metastatic urothelial carcinoma in another [ 38 ]. Affected patients were adults with a median age of 36.5 years (range: 22–65 years) and were more frequently female (10 women, 8 men) [ 7 , 32 , 33 , 37 ]. Reported comorbidities included autoimmune thyreoiditis (Hashimoto's disease), asthma, smoking history, prior COVID-19 infection, and metastatic urothelial carcinoma treated with immune checkpoint inhibitors [ 2 , 7 , 37 , 38 ]. In non-sarcoidosis cases, patients most often presented with painless cervical, axillary, or inguinal lymphadenopathies detected either on self-examination or incidentally [ 30–33 ]. One patient exhibited a chronic allergic tattoo reaction characterized by cutaneous changes, generalized lymphadenopathy, fatigue, and reduced quality of life [ 2 ]. Laboratory abnormalities included mild leukopenia, eosinophilia, elevated lactate dehydrogenase (LDH) or C-reactive protein (CRP) levels [ 2 , 31 ]. Additionally, PET-CT frequently demonstrated FDG-avid lymph nodes with standardized uptake value (SUV) ranging from 7 to 18, initially suggestive of lymphoma and prompting biopsy [ 30 , 31 ]. Patients with sarcoidosis more commonly exhibited systemic symptoms beyond generalized lymphadenopathy (7 out of 13), including exertional dyspnea, cough, erythema nodosum, arthralgia, and fever [ 10 , 29 ]. Ocular involvement with macular edema was reported in two cases [ 26 , 34 ]. Laboratory findings included elevated angiotensin-converting enzyme (ACE) levels, hypercalcemia, inflammatory markers, or an increased CD4/CD8 ratio in bronchoalveolar lavage (BAL) fluid [ 10 , 37 ]. Comprehensive sarcoidosis evaluation also encompassed chest imaging showing hilar/mediastinal lymphadenopathy, frequently with pulmonary nodules, ophthalmologic examination, and tissue biopsy [ 29 , 34 ]. Histopathological examination revealed three distinct patterns. First, non-granulomatous reactive lymphadenopathy with pigment-laden macrophages and sinus histiocytosis was observed in several non-sarcoid cases [ 31–33 ]. Second, granulomatous hypersensitivity characterized by epithelioid granulomas containing black pigment was identified in a single case associated with chronic allergic reaction [ 2 ]. And third, non-caseating granulomas diagnostic of sarcoidosis were found in 12 cases [ 27 , 29 , 34 ], with one additional case confirmed clinically by Löfgren's syndrome [ 8 ]. In non-sarcoidosis cases, the lymphadenopathy resolved following systemic corticosteroid therapy or avoidance of the presumed tattoo-related antigen [ 31 ]. One report described a spontaneous lymphadenopathy regression, after diagnostic excision of a single affected lymph node without further intervention [ 30 ]. By contrast, the chronic allergic reaction required prolonged immunosuppression and ultimately surgical tattoo removal to achieve sustained remission [ 2 ]. In another non-sarcoid patient, lymphadenopathy persisted at one-year follow-up despite excisional biopsy of one affected lymph node, however the patient remained asymptomatic and clinically stable [ 32 ]. Among sarcoidosis cases, outcomes ranged from spontaneous resolution without systemic therapy to improvement following systemic corticosteroid treatment [ 10 , 34 ]. Spontaneous regression of lymphadenopathy was reported in one case [ 10 ], whereas most treated patients required oral or intravenous corticosteroids to achieve clinical improvement or resolution [ 5 , 26 , 29 ]. In contrast, treatment with local corticosteroids alone did not result in sustained improvement where reported, including one patient with persistent disease after two months of topical corticosteroid therapy and another with ongoing symptoms of unspecified duration [ 7 , 35 ]. Additional immunomodulatory agents, including methotrexate, tumor necrosis factor (TNF) inhibitors, or hydroxychloroquine, were used in selected cases, typically in combination with systemic corticosteroids rather than as monotherapy [ 8 , 18 , 37 ]. Notably, TNF inhibitors like adalimumab enabled corticosteroid tapering to monotherapy in one refractory case with intolerable steroid side effects [ 8 ]. Their independent efficacy therefore remains largely unassessed across the series. Overall, improvement of tattoo-associated cutaneous manifestations and lymphadenopathy generally paralleled systemic disease control [ 34 , 37 ]. No malignant transformation was observed, although long-term follow-up was inconsistently reported [ 28 , 36 ]. Across the included reports, tattoo-associated lymphadenopathy frequently posed diagnostic challenges, as affected lymph nodes appeared FDG-avid on PET-CT and were initially interpreted as suspicious for malignancy [ 15 , 30 , 31 ]. Such findings occurred across diverse clinical contexts, including otherwise healthy individuals undergoing diagnostic evaluation [ 31 ], as well as patients with prior or concurrent malignancy (e.g., Hodgkin lymphoma, melanoma), prompting repeat oncologic workup [ 3 , 15 ]. In several cases, this resulted in invasive procedures such as excisional biopsy or lymphadenectomy, which ultimately revealed benign pigment-related or granulomatous changes [ 14 , 16 ]. Collectively, these observations underscore the risk of overtreatment as well as the psychological burden associated with suspected malignancy, including fear of new diagnosis, recurrence, or disease progression [ 20 ]. Conversely, tattoo-related cutaneous lesions and pigment-laden lymph nodes provided an important diagnostic opportunity in a subset of patients [ 27 , 35 , 37 ]. In several sarcoidosis cases, inflammatory changes within tattoos or tattoo-draining lymph nodes prompted further evaluation and ultimately led to the diagnosis of systemic granulomatous disease [ 29 , 38 ]. Notably, in some reports, cutaneous manifestations preceded pulmonary or other organ involvement [ 7 , 35 ]. Finally, lymphadenopathy occurred after laser tattoo removal, immune checkpoint inhibitor therapy, or vaccination in several cases [ 22 , 37 , 38 ].

All clinical cases included in this review are summarized in the Supplementary Table 1 . Although tattoo pigment deposition in lymph nodes has been described in narrative pathology reports for several decades [ 39 ], the available evidence remains fragmented and unsystematically reported. This systematic review synthesizes the literature on tattoo-associated lymphadenopathy as a spectrum ranging from localized pigment deposition to multisite granulomatous disease in the context of sarcoidosis. In doing so, this review provides a structured overview of clinical patterns, diagnostic pathways, and reported outcomes by bringing together previously scattered case reports and small case series. Across the reviewed literature, two principal clinical patterns emerged. Localized lymphadenopathy was usually limited to regional lymph nodes anatomically associated with the tattoo site and characterized histologically by pigment-laden macrophages [ 4 , 9 , 25 ]. In contrast, generalized lymphadenopathy, frequently involving hilar or mediastinal lymph nodes, occurred predominantly though not exclusively, in patients with confirmed sarcoidosis and was commonly accompanied by granulomatous changes in tattooed skin [ 5 , 10 , 34 ]. Interestingly, in all reported cases without confirmed sarcoidosis, tattoo pigment was also identified in biopsied lymph nodes [ 2 , 30–33 ]. However, the relationship between pigment deposition and generalized lymphadenopathy in these cases remains unclear. Together, these findings highlight the heterogeneity of tattoo-associated lymphadenopathy and indicate that localized and generalized presentations likely reflect distinct biological processes. The distinct clinical patterns observed in this review can be interpreted in the context of lymphatic and immunological principles. In localized cases, lymphadenopathy was confined to lymph nodes anatomically draining the tattooed skin and characterized histologically by pigment-laden macrophages within dilated sinuses, without granuloma formation [ 4 , 17 , 20 ]. This distribution strongly supports a mechanism of passive lymphatic transport of tattoo pigment [ 20 , 25 , 40 ]. Following tattooing, ink particles are phagocytosed by dermal macrophages and eventually transported via lymphatic pathways to regional lymph nodes [ 40 ], where they may persist and induce reactive sinus hyperplasia [ 32 ]. The consistent histopathological pattern observed in localized cases argues against predominant systemic immune activation and instead may suggest a benign response against foreign material. By contrast, generalized lymphadenopathy, particularly involving hilar or mediastinal lymph nodes, appears to reflect a different biological process. In patients with sarcoidosis, tattoo pigment was frequently associated with granulomatous inflammation in tattooed skin and lymph nodes [ 5 , 10 , 35 , 37 ]. Consistent with current models of sarcoidosis as a disease of persistent antigen-driven immune dysregulation [ 13 ], these findings suggest that tattoo pigment may act as a persistent immunologic stimulus within a systemically dysregulated immune environment. The frequent requirement for systemic immunosuppressive therapy in these cases further supports immune amplification rather than simple accumulation as the dominant mechanism [ 29 , 34 , 38 ]. Several additional observations indicate that tattoo pigment may function as a trigger or amplifier of immune responses rather than a continuous primary etiologic factor. First, the often prolonged latency between tattoo placement and clinical manifestation argues against direct toxicity [ 7 ,  26 , 28 ]. Second, episodes of lymphadenopathy occurring after immune-modulating events such as laser tattoo removal, immune checkpoint inhibitor therapy, or vaccination are consistent with renewed antigen exposure or altered antigen processing, as these events preceded symptom onset in the reported cases [ 22 , 37 , 38 ]. In particular, laser tattoo removal may promote acute lymphatic dissemination of fragmented pigment particles and potentially modify their immunogenic properties, although the precise mechanisms remain incompletely understood [ 22 ]. Taken together, these findings suggest a model in which localized tattoo-associated lymphadenopathy reflects physiological lymphatic clearance of pigment [ 18 , 40 ], whereas generalized lymphadenopathy arises when tattoo pigment interacts with systemic immune dysregulation [ 13 , 37 ]. While the available evidence does not allow definitive conclusions regarding causality, the observed patterns support a role for tattoo pigment as a biologically relevant co-factor in selected patients as opposed to a universally pathogenic agent [ 7 , 8 , 23 , 30 , 40 ]. In line with chronic inflammatory activation, affected lymph nodes often showed marked FDG uptake on PET-CT, which later proved to reflect benign pigment-associated or granulomatous inflammation rather than malignancy [ 5 , 30 , 31 ]. Across both localized and generalized presentations, tattoo-associated lymphadenopathy frequently posed a diagnostic challenge in clinical practice, particularly in the context of oncologic imaging [ 3 , 16 , 19 ]. A recurrent finding across the reviewed cases was increased metabolic activity of affected lymph nodes on CT or PET-CT, often eliciting concern for malignant involvement [ 28 , 30 , 31 ]. Although FDG uptake is not tumor-specific and may reflect inflammatory or granulomatous processes driven by activated macrophages and lymphocytes, FDG-avid lymph nodes were commonly interpreted as suspicious for metastatic disease in the reviewed cases [ 15 , 30 ]. Pigment-associated or sarcoid-related lymphadenopathy frequently demonstrated marked FDG uptake, sometimes reaching levels typically associated with malignancy, making differentiation based on imaging alone often unreliable [ 16 , 20 , 30 ]. This diagnostic ambiguity had concrete clinical consequences. In several patients, PET-positive lymph nodes prompted invasive diagnostic procedures, including lymph node biopsy or surgical excision, primarily to exclude malignancy, carrying risks of lymphedema and infection [ 15 , 19 , 20 , 41 ]. In oncologic settings, hypermetabolic lymph nodes led to repeat staging evaluations, interruption of ongoing systemic therapy, or surgical interventions due to concerns for progression or metastasis [ 16 , 17 , 38 ]. Intraoperatively, dark or discolored lymph nodes further heightened suspicion for metastatic disease before histopathological examination revealed pigment-laden macrophages rather than tumor infiltration [ 14 , 25 , 30 ]. One reported case illustrates the potential severity of such misinterpretation [ 38 ]. Sarcoidosis-associated hilar lymphadenopathy arose during immune checkpoint inhibitor therapy for metastatic urothelial carcinoma and was initially attributed to tumor progression, leading to interruption of immunotherapy. Histopathological examination of a skin biopsy confirmed sarcoidosis and treatment with hydroxychloroquine and methylprednisolone was initiated. While sarcoidosis symptoms improved, staging subsequently revealed cancer progression and the patient ultimately died from malignancy [ 38 ]. Although causality cannot be definitively established, this case highlights the potential clinical impact of misclassifying tattoo- or sarcoid-associated lymphadenopathy as tumor progression. Collectively, these observations indicate that tattoo-associated lymphadenopathy represents a clinically relevant and under-recognized diagnostic pitfall, with risks of overtreatment, interruption of effective oncologic therapy and psychological distress arising from suspected malignancy [ 14 , 20 , 38 ]. This systematic review has several methodological and content-related limitations. First, the available evidence consists exclusively of case reports and small case series, which limits generalizability and quantitative analysis. Second, all cases were identified using specific search terms within the PubMed database only. Therefore, relevant literature not captured by these terms or indexed elsewhere may have been missed. Furthermore, reporting across cases was heterogeneous, particularly regarding latency between tattooing and clinical presentation, treatment details, and outcome. In addition, publication bias toward unusual or diagnostically challenging cases is likely. Finally, although a structured search strategy was applied, errors in the search process and data extraction cannot be completely excluded. In summary, this systematic review demonstrates that tattoo-associated lymphadenopathy represents a clinical spectrum ranging from localized pigment clearance to generalized granulomatous disease, often observed in the context of sarcoidosis. By synthesizing previously scattered case reports and small case series, this review addresses a relevant gap in the literature and provides a structured framework for understanding the clinical, pathological, and diagnostic features of this underrecognized phenomenon. The reviewed evidence suggests that localized patterns reflect passive lymphatic transport to draining nodes [ 18 , 25 , 40 ]. In contrast, generalized forms appear to involve tattoo pigment acting as an immunologic co-factor, often amplified by triggers like laser removal, checkpoint inhibitors, or vaccination [ 22 , 37 , 38 ]. From a clinical perspective, the key implication is the importance of thorough tattoo anamnesis when evaluating unexplained lymphadenopathy. This includes current and prior tattoos, cosmetic tattooing, and any history of laser tattoo removal. Such information is particularly relevant in patients with FDG-avid lymph nodes on PET-CT, where tattoo-associated or granulomatous inflammation may closely mimic malignant disease. While histopathological examination remains the diagnostic gold standard, awareness of this entity can help to reduce unnecessary invasive procedures, avoid inappropriate disease upstaging, prevent interruption of effective oncologic therapies, and mitigate the psychological burden associated with suspected malignancy. Importantly, the available evidence suggests that tattoo pigment is unlikely to represent a universally pathogenic agent. Instead, it may act as a biologically relevant co-factor or immune trigger in selected patients, particularly in the presence of systemic immune dysregulation such as sarcoidosis or exposure to immune-modulating therapies [ 8 , 38 ]. Conversely, accessible peripheral lymphadenopathy or tattoo-site changes in patients with sarcoidosis may enable earlier diagnosis than typically possible with pulmonary presentations [ 10 , 35 ]. However, the evidence remains insufficient to establish causality in cases of generalized lymphadenopathy, underscoring the need for cautious interpretation. Several questions remain unanswered. Factors predisposing certain individuals to generalized or sarcoid-like reactions, the role of specific ink components or colors, and the influence of comorbidities such as autoimmune disease, malignancy, or immune checkpoint inhibitor therapy are not well defined. Likewise, the immunological consequences of laser tattoo removal and the mechanisms underlying delayed disease flares warrant further investigation. Future research should move beyond isolated case reports towards systematic, multicenter data collection with standardized reporting of clinical presentation, imaging findings, histopathology, and outcomes. Such efforts are necessary to clarify pathophysiological mechanisms, identify potential risk factors, and support evidence-based diagnostic and management strategies. In conclusion, as tattoo prevalence continues to rise, tattoo-associated lymphadenopathy including generalized/systemic manifestation will likely be encountered more frequently across medical specialties. Recognition of its variable presentation and integration of clinical history, imaging findings, and histopathology are essential to ensure accurate diagnosis and appropriate patient care.

Tattoos have become increasingly popular in recent decades. In fact, approximately 11.7 to 31.5% of the population are estimated to have at least one tattoo, and tattoo prevalence peaks in adults aged 25–34 years [ 1 ]. Tattooing involves the injection of pigments into the dermis using needles, most often performed in professional studios [ 2–6 ]. However, the components of tattoo inks are only partly regulated regarding safety issues (i.e., toxicity aspects) and may contain organic pigments and heavy metals that can persist in tissues and provoke local or even systemic immune responses [ 1 ]. Although professional tattooing is generally considered safe, a broad range of complications has been reported, including infections, allergic reactions, and granulomatous inflammatory responses, sometimes even in association with systemic sequelae [ 5 , 7 ]. Moreover, given that tattoo pigments may be drained to regional lymph nodes and elicit pro-inflammatory immune reactions [ 3 , 8 , 9 ], tattooing has been linked to lymphadenopathies. In some cases, the immunopathological collateral damages may manifest as granulomatous disease involving lymph nodes or even systemic/generalized manifestations [ 8 , 10 ]. Lymphadenopathy describes a clinical condition that is characterized by an abnormal change in the size and/or consistency of lymph nodes and represents a frequent clinical finding in diverse medical contexts [ 11 ]. In general, lymph nodes larger than 1 cm are considered enlarged, although size criteria vary depending on patient age and anatomical location [ 12 ]. Lymphadenopathy may arise as a reaction to various conditions, including infections, malignancies, and inflammatory diseases such as sarcoidosis [ 11 ,  13 ]. Clinically, it is commonly divided into localized and generalized forms, depending on whether one or multiple non-contiguous lymph node regions are affected [ 14 ]. While this distinction helps to narrow the differential diagnosis [ 11 ], many lymphadenopathies remain clinically silent and are discovered incidentally. In some cases, they are detected on imaging studies, such as magnetic resonance imaging (MRI), computed tomography (CT), or on positron emission tomography-computed tomography (PET-CT) when showing high fluorodeoxyglucose (FDG) uptake [ 4 , 15 ]. In this context, it is noteworthy that foreign materials, such as tattoo pigments, can accumulate in regional lymph nodes, where they may induce reactive hyperplasia and lead to lymph node enlargement and discoloration [ 15 ]. Localized lymphadenopathies involve a single anatomical region (e.g., cervical, axillary, inguinal) and account for approximately 75% of lymphadenopathy cases, with more than 50% occurring in the head and neck regions [ 12 ]. In clinical practice, common causes include infectious diseases and neoplasms [ 12 ]. However, localized lymphadenopathies may also result from the drainage of exogenous material, such as tattoo pigments, to the corresponding regional lymph nodes [ 4 ,  15–17 ]. In contrast, generalized lymphadenopathy involves multiple non-contiguous lymph node regions and may also include thoracic lymph nodes such as the hilar or mediastinal stations [ 12 ]. This pattern often indicates an underlying systemic disease such as sarcoidosis [ 12 ]. Given its strong association with lymph node involvement [ 13 ] and its relevance in tattoo-associated cases, sarcoidosis is discussed in detail in the following paragraph. Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that most commonly affects the lungs and thoracic lymph nodes [ 13 ]. In Europe, the annual incidence of sarcoidosis is estimated approximately 5 to 60 per 100,000, with a peak in adults aged 20–40 years. Notably, lymphadenopathy occurs in 70 to 90% of patients and typically involves the bilateral hilar and mediastinal lymph nodes. This characteristic distribution underscores the relevance of sarcoidosis in the differential diagnosis of generalized lymphadenopathy, including tattoo-associated cases [ 13 ]. Standard evaluation of lymphadenopathies primarily focuses on infections, malignancies, and autoimmune diseases [ 11 ,  12 ]. However, despite increasing prevalence of tattoos and a growing number of published case reports, the potential contribution of tattoo pigment drainage to the development of lymphadenopathies is rarely considered in clinical practice [ 4 , 10 ]. This prompted us to systematically summarize existing evidence from the literature regarding local and generalized tattoo-associated lymphadenopathy, including sarcoidosis, to identify clinical patterns, diagnostic challenges, and implications for patient management.

The literature research for this review was performed on November 25th, 2025 by using the online meta database “PubMed” by the U.S. National Library of Medicine (NLM), which combines access to several databases for medical and biomedical literature. The search terms tattoo “AND” lymphadenopathy provided a total of 44 results ( Fig. 1 ). After assessment for eligibility, 33 publications were included in the qualitative synthesis and transferred to a table for systematic evaluation. The following data were extracted: year of publication, patient age and relevant medical history, characteristics of the tattoo, clinical presentation and symptoms, localization of lymphadenopathy, histological findings (including confirmation of sarcoidosis where applicable), diagnostic procedures, diagnosis, treatment, and outcome. Given the rarity of tattoo-associated lymphadenopathies including sarcoidosis, predominantly case reports were identified. PRISMA 2020 flow diagram of the literature selection process This review included pigment-related local (e.g., axillary, inguinal) and generalized (e.g., hilar, mediastinal) lymphadenopathies with the latter occurring in frame of tattoo-associated sarcoidosis. Inclusion required documented presence of a tattoo or prior removal (e.g., professional laser treatment or dermabrasion) with correlation to lymphadenopathy, meaning either detection of tattoo pigment in lymph node biopsy or non-caseating granulomas in tattoo lesions/lymph nodes with confirmed sarcoidosis diagnosis. Furthermore, prerequisite conditions for inclusion were sufficient clinical and histopathological details of the publications. Therefore, narrative articles and non-systematic reports were excluded from the formal synthesis but considered for contextual discussion. Isolated cutaneous tattoo reactions, like allergies or infections, as well as tattoo-associated uveitis without lymph node involvement were also excluded. After applying these criteria 11 publications were excluded, and 33 papers remained for final content analysis ( Fig. 1 ).